These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 2836627)

  • 1. Cell-mediated immunity induced in mice after vaccination with a protease activation mutant, TR-2, of Sendai virus.
    Tashiro M; Fujii Y; Nakamura K; Homma M
    J Virol; 1988 Jul; 62(7):2490-7. PubMed ID: 2836627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a protease activation mutant of Sendai virus as a potent live vaccine.
    Maru M; Haraguchi M; Sato K; Hotta H; Homma M
    Vet Microbiol; 1992 Jan; 30(1):1-12. PubMed ID: 1311131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide.
    Kast WM; Roux L; Curren J; Blom HJ; Voordouw AC; Meloen RH; Kolakofsky D; Melief CJ
    Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2283-7. PubMed ID: 1848698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aerosol vaccination with a sendai virus temperature-sensitive mutant (HVJ-pB) derived from persistently infected cells.
    Iwata H; Tagaya M; Matsumoto K; Miyadai T; Yokochi T; Kimura Y
    J Infect Dis; 1990 Aug; 162(2):402-7. PubMed ID: 1695654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumopathogenicity in mice of a Sendai virus mutant, TSrev-58, is accompanied by in vitro activation with trypsin.
    Mochizuki Y; Tashiro M; Homma M
    J Virol; 1988 Aug; 62(8):3040-2. PubMed ID: 2839720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A protease activation mutant, MVCES1, as a safe and potent live vaccine derived from currently prevailing Sendai virus.
    Wang XL; Itoh M; Hotta H; Homma M
    J Virol; 1994 May; 68(5):3369-73. PubMed ID: 8151795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic interactions of virus specific effector cells with virus infected targets of different cell type.
    Koszinowski U; Ertl H
    J Immunogenet; 1977 Apr; 4(2):107-14. PubMed ID: 194984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of mice from wild-type Sendai virus infection by a trypsin-resistant mutant, TR-2.
    Tashiro M; Homma M
    J Virol; 1985 Jan; 53(1):228-34. PubMed ID: 2981341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of CD8+ T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination.
    Chen Y; Webster RG; Woodland DL
    J Immunol; 1998 Mar; 160(5):2425-32. PubMed ID: 9498786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
    Morrison LA; Knipe DM
    Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term CD8+ T cell memory to Sendai virus elicited by DNA vaccination.
    Chen Y; Usherwood EJ; Surman SL; Hogg TL; Woodland DL
    J Gen Virol; 1999 Jun; 80 ( Pt 6)():1393-1399. PubMed ID: 10374956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient priming of CD8+ memory T cells specific for a subdominant epitope following Sendai virus infection.
    Cole GA; Hogg TL; Coppola MA; Woodland DL
    J Immunol; 1997 May; 158(9):4301-9. PubMed ID: 9126992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination.
    Kast WM; Brandt RM; Melief CJ
    Eur J Immunol; 1993 May; 23(5):1189-92. PubMed ID: 8386667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells.
    Kast WM; Boog CJ; Roep BO; Voordouw AC; Melief CJ
    J Immunol; 1988 May; 140(9):3186-93. PubMed ID: 2834454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organ tropism of Sendai virus in mice: proteolytic activation of the fusion glycoprotein in mouse organs and budding site at the bronchial epithelium.
    Tashiro M; Yamakawa M; Tobita K; Klenk HD; Rott R; Seto JT
    J Virol; 1990 Aug; 64(8):3627-34. PubMed ID: 2164589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral cytotoxic T-cell memory by vaccination with recombinant Listeria monocytogenes.
    Slifka MK; Shen H; Matloubian M; Jensen ER; Miller JF; Ahmed R
    J Virol; 1996 May; 70(5):2902-10. PubMed ID: 8627765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK.
    Gyotoku T; Ono F; Aurelian L
    Vaccine; 2002 Jun; 20(21-22):2796-807. PubMed ID: 12034107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Joint recognition by cytotoxic T cells of inactivated Sendai virus and products of the major histocompatibility complex.
    Schrader JW; Edelman GM
    J Exp Med; 1977 Mar; 145(3):523-39. PubMed ID: 233918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses.
    Selin LK; Nahill SR; Welsh RM
    J Exp Med; 1994 Jun; 179(6):1933-43. PubMed ID: 8195718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperation between humoral factor(s) and Lyt-2+ T cells in effective clearance of Sendai virus from infected mouse lungs.
    Iwai H; Yamamoto S; Otsuka Y; Ueda K
    Microbiol Immunol; 1989; 33(11):915-27. PubMed ID: 2574407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.